Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lomas, M.
Right arrow Articles by Ward, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lomas, M.
Right arrow Articles by Ward, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:324-329, 2004
© 2004 European Society for Medical Oncology

Original Paper

Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy

Received 1 May 2003; revised 18 August 2003; accepted 29 September 2003;

Background:

The purpose of this study was to induce immunity to p53 by using an idiotypic vaccine, composed of a pool of eight peptides derived from the complimentarity determining regions (CDRs) of human anti-p53 antibodies.

Patients and methods:

Subjects with advanced malignancy received up to four, monthly intradermal injections of pooled peptides (500 µg of each) admixed with granulocyte–macrophage colony-stimulating factor (GM-CSF; 100 µg). In addition, two sheep and two rabbits were also vaccinated with the pooled peptides.

Results:

Fourteen subjects were enrolled into the study and six of these completed the vaccination schedule. The vaccine was well tolerated by all subjects and no major adverse events were attributable to the vaccine. All subjects mounted in vivo delayed type hypersensitivity (DTH) responses to two or more of the individual vaccine peptides. Vaccine-induced antibodies specific for peptides 2, 5 or 8 were detected in four of six subjects, and two of these had vaccine-specific, cell-mediated responses. Increasing titers of p53-specific antibodies were found in one patient. No T-cell response to p53 was observed in any of the subjects. All animals developed humoral immunity to the peptides and one of the sheep developed rising serum titers of anti-p53 antibodies.

Conclusions:

Vaccination with human antibody CDR regions represents a novel method for inducing human antibodies, which may in turn serve as immunological mimics of p53.

M. Lomas1, W. Liauw1,2, D. Packham1, K. Williams2, A. Kelleher3, J. Zaunders3 and R. Ward1,4,*

1 Department of Medical Oncology, 2 Clinical Trials Unit and 3 Centre for Immunology, St Vincent’s Hospital, Darlinghurst; 4 School of Medicine, University of New South Wales, Sydney, Australia

Key words: cancer, idiotype, p53, vaccination


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. LaFevre-Bernt, S. Wu, and X. Lin
Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1420 - 1429.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.